MDT
97.97
-0.41%ā
VEEV
301.82
-1.22%ā
A
141.04
+1.79%ā
HQY
92.06
+4.03%ā
PHR.US
23.23
-0.43%ā
MDT
97.97
-0.41%ā
VEEV
301.82
-1.22%ā
A
141.04
+1.79%ā
HQY
92.06
+4.03%ā
PHR.US
23.23
-0.43%ā
MDT
97.97
-0.41%ā
VEEV
301.82
-1.22%ā
A
141.04
+1.79%ā
HQY
92.06
+4.03%ā
PHR.US
23.23
-0.43%ā
MDT
97.97
-0.41%ā
VEEV
301.82
-1.22%ā
A
141.04
+1.79%ā
HQY
92.06
+4.03%ā
PHR.US
23.23
-0.43%ā
MDT
97.97
-0.41%ā
VEEV
301.82
-1.22%ā
A
141.04
+1.79%ā
HQY
92.06
+4.03%ā
PHR.US
23.23
-0.43%ā
24u
Huidig
Min
2.87
Max
3.04
Aanbevelingen | Buy |
---|---|
12 Maanden Prognose | +375.41% upside |
Volgende Winsten | 12 nov 2025 |
---|
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
1 okt 2025, 15:07 UTC
Fortress Biotech Shares Drop After FDA Letter for CUTX-101 Manufacturing Facility
DJ
Lezen
10 mrt 2025, 02:12 UTC
Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY
DJ
Lezen
10 mrt 2025, 02:12 UTC
Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY
DJ
Lezen
10 mrt 2025, 02:11 UTC
Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY
DJ
Lezen
10 mrt 2025, 02:11 UTC
Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 if Cosibelimab if Approved in EU Prior to Certain Deadlines >524715.BY
DJ
Lezen
10 mrt 2025, 02:10 UTC
Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY
DJ
Lezen
10 mrt 2025, 02:10 UTC
Sun Pharma to Acquire Checkpoint Therapeutics >524715.BY CKPT
DJ
Lezen
10 mrt 2025, 02:06 UTC
Sun Pharma To Acquire Checkpoint Therapeutics >524715.BY CKPT
DJ
Lezen
Prijswijziging
By TipRanks
12 Maanden Prognose
Gemiddelde 14.5Ā USDĀ 375.41%
Hoogste 17Ā USD
Laagste 12Ā USD
Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fortress Biotech Inc - Dist. in de afgelopen 3 maanden.
By TipRanks
Buy
2 ratings
2
Buy
0
Hold
0
Sell
Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Fortress Biotech Inc - Dist in de afgelopen 3 maanden.
$